首页> 外文期刊>Bone >Selective inhibition of Src family kinases by SU6656 increases bone mass by uncoupling bone formation from resorption in mice
【24h】

Selective inhibition of Src family kinases by SU6656 increases bone mass by uncoupling bone formation from resorption in mice

机译:SU6656通过从小鼠吸收的骨形成,SU6656对SRC系列激酶的选择性抑制增加了骨质

获取原文
获取原文并翻译 | 示例
           

摘要

Mice deficient in the non-receptor tyrosine kinase Src exhibit high bone mass due to impaired bone resorption and increased bone formation. Although several Src family kinase inhibitors inhibit bone resorption in vivo, they display variable effects on bone formation. SU6656 is a selective Src family kinase inhibitor with weaker activity towards the non-receptor tyrosine kinase Abl and receptor tyrosine kinases which are required for appropriate osteoblast proliferation, differentiation and function. Therefore, we sought to determine whether SU6656 could increase bone mass by inhibiting bone resorption and by stimulating bone formation, and to explore its mechanisms of action. Four-month-old female C57BI/6J mice received intraperitoneal injections of either 25 mg/kg SU6656 or its vehicle every other day for 12 weeks. SU6656-treated mice exhibited increased bone mineral density, cortical thickness, cancellous bone volume and trabecular thickness. SU6656 inhibited bone resorption in mice as shown by reduced osteoclast number, and diminished expressions of Oscar, Trap5b and CtsK. SU6656 did not affect Rankl or Opg expressions. However, it blocked c-fms signaling, osteoclastogenesis and matrix resorption, and induced osteoclast apoptosis in vitro. In addition, SU6656 stimulated bone formation rates at trabecular, endosteal and periosteal bone envelopes, and increased osteoblast number in trabecular bone. SU6656 did not affect expressions of clastokines favoring bone formation in mice. However, it stimulated osteoblast differentiation and matrix mineralization by specifically facilitating BMP-SMAD signaling pathway in vitro. Knockdown of Src and Yes mimicked the stimulatory effect of SU6656 on osteoblast differentiation. In conclusion, SU6656 uncouples bone formation from resorption by inhibiting osteoclast development, function and survival, and by enhancing BMP-mediated osteoblast differentiation.
机译:缺乏非受体酪氨酸激酶SRC的小鼠由于骨吸收受损和骨形成增加而表现出高骨量。虽然几种SRC系列激酶抑制剂抑制体内骨吸收,但它们显示对骨形成的可变效应。 SU6656是一种选择性SRC系列激酶抑制剂,其活性较弱,朝向非受体酪氨酸激酶ABL和受体酪氨酸激酶,这是适当的成骨细胞增殖,分化和功能所必需的。因此,我们试图通过抑制骨吸收并通过刺激骨形成,探讨其作用机制,试图确定SU6656是否可以通过抑制骨吸收和抗骨骼形成来增加骨质量。每隔一天持续12周龄C57Bi / 6J小鼠每隔一天接受25mg / kg SU6656或其车辆的腹腔注射12周。 SU6656治疗的小鼠表现出骨矿物密度增加,皮质厚度,松质骨体积和小梁厚度。 SU6656抑制小鼠中的骨吸收,如减少的骨细胞数所示,奥斯卡,Trap5b和CTSK的表达减少。 SU6656不会影响Rankl或OPG表达式。然而,它阻断了C-FMS信号,骨骨细胞发生和基质再吸收,并在体外诱导骨质体细胞凋亡。此外,SU6656在小梁,内皮和骨膜骨封包膜上刺激骨形成速率,以及在小梁骨中增加的成骨细胞数。 SU6656不影响患者骨形成的氏菌素的表达。然而,它通过特异性地促进体外BMP-Smad信号通路来刺激成骨细胞分化和基质矿物化。 SRC敲低和是模仿SU6656对成骨细胞分化的刺激作用。总之,SU6656通过抑制破骨细胞发育,功能和存活,并通过增强BMP介导的成骨细胞分化来脱离骨形成。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号